Fetal and neonatal alloimmune thrombocytopenia

Best Practice and Research in Clinical Obstetrics and Gynaecology

Volumn 22, Issue 1, 2008, Pages 3-14

  van den Akker, Eline S A ^a   Oepkes, Dick ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

alloimmune thrombocytopenia; fetal blood sampling; human platelet antigens; intracranial haemorrhage; intravenous immunoglobulin

Indexed keywords

ALLOANTIBODY; CORTICOSTEROID; DEXAMETHASONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MATERNAL ANTIBODY; PLACEBO; PREDNISONE; THROMBOCYTE ANTIGEN;

ALLOIMMUNITY; BRAIN HEMORRHAGE; CAUCASIAN; CESAREAN SECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DELIVERY; DISEASE SEVERITY; ELECTIVE SURGERY; FETUS BLOOD SAMPLING; FETUS DISEASE; HUMAN; INCIDENCE; INTRAUTERINE BLOOD TRANSFUSION; MONOTHERAPY; NEUROLOGIC DISEASE; NEWBORN DISEASE; NON INVASIVE PROCEDURE; PRENATAL CARE; PRIORITY JOURNAL; REVIEW; SCREENING TEST; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ANTIGENS, HUMAN PLATELET; FEMALE; FETAL DISEASES; FETAL THERAPIES; HUMANS; INFANT, NEWBORN; INTRACRANIAL HEMORRHAGES; PREGNANCY; PRENATAL CARE; PRENATAL DIAGNOSIS; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 39049123677     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2007.08.001     Document Type: Review

References (58)

1. Bussel J.B., Zacharoulis S., Kramer K., et al. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr Blood Cancer 45 2 (2005) 176-183
2. Dreyfus M., Kaplan C., Verdy E., et al. Frequency of immune thrombocytopenia in newborns: a prospective study. Blood 89 12 (1997) 4402-4406
3. Burrows R.F., and Kelton J.G. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med 329 20 (1993) 1463-1466
4. Roberts I., and Murray N.A. Neonatal thrombocytopenia: causes and management. Arch Dis Child Fetal Neonatal Ed 88 5 (2003) F359-F364
5. Sainio S., Jarvenpaa A.L., Renlund M., et al. Thrombocytopenia in term infants: a population-based study. Obstet Gynecol 95 3 (2000) 441-446
6. de Moerloose P., Boehlen F., Extermann P., et al. Neonatal thrombocytopenia: incidence and characterization of maternal antiplatelet antibodies by MAIPA assay. Br J Haematol 100 (1998) 735-740
7. Bussel J.B., Zabusky M.R., Berkowitz R.L., et al. Fetal alloimmune thrombocytopenia. N Engl J Med 337 (1997) 22-24
8. Kaplan C., Murphy M.F., Kroll H., et al. Feto-maternal alloimmune thrombocytopenia: antenatal therapy with IvIgG and steroids-more questions than answers. European Working Group on FMAIT. Br J Haematol 100 (1998) 62-65
9. Blanchette V.S., Chen L., de Friedberg Z.S., et al. Alloimmunization to the PlA1 platelet antigen: results of a prospective study. Br J Haematol 74 2 (1990) 209-215
10. Durand-Zaleski I., Schlegel N., Blum-Boisgard C., et al. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Am J Perinatol 13 7 (1996) 423-431
11. Williamson I.M., Hackett G.A., Rennie J.M., et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PLA1, Zwa) as determined by antenatal screening. Blood 92 (1995) 2280-2287
12. Maslanka K., Guz K., and Zupanska B. Antenatal screening of unselected pregnant women for HPA-1a antigen, antibody and alloimmune hrombocytopenia. Vox Sang 85 4 (2003) 326-327
13. Davoren A., McParland P., Crowley J., et al. Antenatal screening for human platelet antigen-1a: results of a prospective study at a large maternity hospital in Ireland. BJOG 110 5 (2003) 492-496
14. Kjeldsen-Kraghl J, Killie MK, Aune B, et al. An intervention program for reducing morbidity and mortality associated with neonatal alloimmune thrombocytopenic purpura. 8th European Symposium on platelet and Granulocyte Immunobiology; 2004, Rust.
15. Turner M.L., Bessos H., Fagge T., et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion 45 12 (2005) 1945-1956
16. Metcalfe P., Watkins N.A., Ouwehand W.H., et al. Nomenclature of human platelet antigens. Vox Sang 85 3 (2003) 240-245
17. Mueller-Eckhardt C., Kiefel V., Grubert A., et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1 (1989) 363-366
18. Spencer J.A., and Burrows R.F. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol 41 (2001) 45-55
19. Murphy M.F., Williamson L.M., and Urbaniak S.J. Antenatal screening for fetomaternal alloimmune thrombocytopenia: should we be doing it?. Vox Sang 83 Suppl. 1 (2002) 409-416
20. Mueller-Eckhardt C., Mueller-Eckhardt G., Willen Ohff H., et al. Immunogenicity of an immune response to human platelet antigen Zw (a) is strongly associated with HLA-B8 and DR3. Tissue Antigens 26 (1985) 71-76
21. Williamson L.M., Lubenko A., Hadfield R., et al. Large-scale genotyping of platelet donors for the platelet-specific alloantigens HPA-1, 2 and 3. Br J Haematol 84 (1993) 7
22. Kim H.O., Jin Y., Kickler T.S., et al. Gene frequencies of the five major human platelet antigens in African American, white, and Korean populations. Transfusion 35 (1995) 863-883
23. Urwijitaroon Y., Barusrux S., Romphruk A., et al. Frequency of human platelet antigens among blood donors in northeastern Thailand. Transfusion 35 (1995) 868-870
24. Simsek S., Faber N.M., Bleeker P.M., et al. Determination of human platelet antigen frequencies in the Dutch population by immunophenotyping and DNA (allele-specific restriction enzyme) analysis. Blood 81 (1993) 835-840
25. Feng M.L., Liu D.Z., Shen W., et al. establishment of an HPA-1- to -16-typed platelet donor registry in China. Transfus Med 16 5 (2006) 369-374
26. Seo D.H., Park S.S., Kim D.W., et al. Gene frequencies of eight human platelet-specific antigens in Koreans. Transfus Med 8 2 (1998) 129-132
27. Kuijpers RWAM. Neonatal alloimmune thrombocytopenia: relation between serological parameters and clinical picture. Thesis: Maastricht University, 1993.
28. Herman J.H., Jumbelic M.I., and Ancona R.J. In utero cerebral hemorrhage in alloimmune thrombocytopenia. Am J Pedaitr Hemotol Oncol 8 (1986) 312-317
29. Bussel J.B., Richard M.D., Berkowitz L., et al. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med 319 (1988) 1374-1378
30. Muller J.Y., Reznikoff-Etievant M.F., Patereau C., et al. Thrombopénies néo-natales allo-immunes étude clinique et biologique de 84 cas. La Presse Médicale 14 (1985) 83-86
31. Kaplan C., Morel-Kopp M.C., Kroll H., et al. HPA-5b (Bra) neonatal alloimmune throbocytopenia: clinical and immunological analysis of 39 cases. Br J Haematol 78 (1991) 425-429
32. Bussel J.B., Berkowitz R.L., Lynch L., et al. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomised trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol 174 (1996) 1414-1423
33. Sharif U., and Kuban K. Prenatal intracranial hemorrhage and neurologic complications in alloimmune thrombocytopenia. J Child Neurol 16 11 (2001) 838-842
34. Kaplan C., Daffos F., Forestier F., et al. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets. Blood 72 (1988) 340-343
35. Proulx C., Filion M.M., Goldman M., et al. Analysis of immunoglobulin class IgG subclass and titre of HPA-1a antibodies in alloimmunised mothers giving birth to babies with or without neonatal alloimmune thrombocytopenia. Br J Haematol 87 (1994) 813-817
36. Metcalfe P., Allen D., Chapman J., et al. Interlaboratory variation in the detection of clinically significant alloantibodies against human platelet alloantigens. Br J Haematol 97 1 (1997) 204-207
37. Jaegtvik S., Husebekk A., Aune B., et al. Neonatal alloimmune thrombocytopenia due to anti-HPA 1a antibodies; the level of maternal antibodies predicts the severity of thrombocytopenia in the newborn. BJOG 107 5 (2000) 691-694
38. Bertrand C., Martageix C., Jallu V., et al. Predictive value of sequential anti-HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia. J Thromb Haemost 4 3 (2006) 628-637
39. Jhawar B.S., Ranger A., Steven D., et al. Risk factors for intracranial hemorrhage among full-term infants: a case-control study. Neurosurgery 52 3 (2003) 581-590
40. Daffos F., Forestier F., Muller J.Y., et al. Prenatal treatment of alloimmune thrombocytopenia. Lancet 2 (1984) 632
41. Radder C.M., Brand A., and Kanhai H.H.H. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?. Vox Sang 84 (2003) 318-325
42. Overton T.G., Duncan K.R., Jolly M., et al. Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal outcome. Am J Obstet Gynecol 186 (2002) 826-831
43. Birchall J.E., Murphy M.F., Kaplan C., et al. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol 122 (2003) 275-288
44. Berkowitz R.L., Kolb E.A., McFarland J.G., et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol 107 (2006) 91-96
45. Wenstrom K.D., Weiner C.P., and Williamson R.A. Antenatal treatment of fetal alloimmune thrombocytopenia. Obstet Gynecol 80 (1992) 433-435
46. Radder C.M., Brand A., and Kanhai H.H.H. A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 185 (2001) 683-688
47. Radder C.M., Kanhai H.H., and Brand A. On the mechanism of high dose maternal intravenous immunoglobulin (IVIG) in alloimmune thrombocytopenia. Management of fetal alloimmune thrombocytopenia (2004), Print Partners Ipskamp, Amsterdam 69-81
48. Radder C.M., de Haan M.J.J., Brand A., et al. Follow up of children after antenatal treatment for alloimmune thrombocytopenia. Early Hum Dev 80 (2004) 65-76
49. Cordonnier C., Chevret S., Legrand M., et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 139 (2003) 8-18
50. Godeau B., Caulier M.T., Decuypere L., et al. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol 107 (1999) 716-719
51. Berkowitz R.L., Bussel J.B., and McFarland J.G. Alloimmune thrombocytopenia: state of the art 2006. Am J Obstet Gynecol 195 (2006) 907-913
52. Van den Akker E.S.A., Oepkes D., Lopriore E., et al. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective. BJOG (2007) [Epub ahead of print]
53. Thung S.F., and Grobman W.A. The cost effectiveness of empiric intravenous immunoglobulin for the antepartum treatment of fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 193 3 Pt 2 (2005) 1094-1099
54. Reznikoff-Etievant M.F. Management of alloimmune neonatal and antenatal thrombocytopenia. Vox Sang 55 (1988) 193-201
55. Van den Akker E.S.A., Oepkes D., Brand A., et al. Vaginal delivery for fetuses at risk of alloimmune thrombocytopenia?. BJOG 113 (2006) 781-783
56. Killie M.K., Husebekk A., Kaplan C., et al. Maternal human platelet antigen-1a antibody level correlates with the platelet count in the newborns: a retrospective study. Transfusion 47 1 (2007) 55-58
57. Skupski D.W., and Bussel J.B. Alloimmune thrombocytopenia. Clin Obstet Gynecol 42 (1999) 335-348
58. Kaplan C. Alloimmune thrombocytopenia of the fetus and the newborn. Blood Rev 16 (2002) 69-72